Open an account

Arcus Biosciences

RCUS · NYSE

$23.75+$1.61 (+7.27%)TodayMarket closed ·
Prev close $22.14

About RCUS

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 601 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Employees
601
Headquarters
Hayward, California
Listed
Mar 15, 2018
Sector
Health Care
Industry
Biotechnology
Website
arcusbio.com

RCUS key statistics

Market cap
3.02B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.47M
Volume
6.24M
Open price
$21.26
High today
$24.70
Low today
$20.81
52 Week high
$31.74
52 Week low
$16.35

Arcus Biosciences (RCUS) at a glance

Arcus Biosciences (RCUS) last traded at $23.75, with a market cap of 3.02B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $20.81 and $24.70. The current price is 14.1% above the day's low and 3.8% below its high.

Volume so far is 6.24M shares, above the average of 1.47M shares a day.

Over the past year Arcus Biosciences has ranged from $16.35 to $31.74, and now sits 48% of the way up that range.

Arcus Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.72 per share against an estimate of -$0.9162.

The average analyst price target is $40.71, 71.4% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

71%of 14 analyst ratings say Buy
  • Buy71.4%
  • Hold28.6%
  • Sell0.0%
Price target · 13 analystsAvg $40.71
Low
$23.23
Now
$23.75
High
$49.35

RCUS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 28.0% on average.

  1. Q3 FY24: reported -$1.00 per share against an estimate of -$1.08
  2. Q4 FY24: reported -$1.03 per share against an estimate of -$1.27
  3. Q1 FY25: reported -$1.14 per share against an estimate of -$1.05
  4. Q2 FY25: reported $0.00 per share against an estimate of -$1.15
  5. Q3 FY25: reported -$1.27 per share against an estimate of -$1.34
  6. Q4 FY25: reported -$0.89 per share against an estimate of -$1.05
  7. Q1 FY26: reported -$1.02 per share against an estimate of -$0.8944
  8. Q2 FY26: reported -$0.72 per share against an estimate of -$0.9162

RCUS news

  • Press releaseBusiness Wire

    Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

  • Press releaseBusiness Wire

    Arcus Biosciences Announces New Employment Inducement Grants

  • Press releaseBusiness Wire

    Arcus Biosciences Announces New Employment Inducement Grants

  • Press releaseBusiness Wire

    Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

  • Press releaseBusiness Wire

    Arcus Biosciences Announces New Employment Inducement Grants

  • Press releaseBusiness Wire

    Arcus Biosciences to Participate in Three Upcoming Investor Conferences

  • Press releasePRNewswire

    Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

  • Press releaseBusiness Wire

    Arcus Biosciences Announces New Employment Inducement Grants

Similar companies

Companies in the same industry as Arcus Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.